Logo image of BU.CA

BURCON NUTRASCIENCE CORP (BU.CA) Stock Fundamental Analysis

TSX:BU - Toronto Stock Exchange - CA1208311029 - Common Stock - Currency: CAD

2.88  +0.03 (+1.05%)

Fundamental Rating

2

Overall BU gets a fundamental rating of 2 out of 10. We evaluated BU against 28 industry peers in the Chemicals industry. BU has a bad profitability rating. Also its financial health evaluation is rather negative. BU is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year BU has reported negative net income.
BU had a negative operating cash flow in the past year.
In the past 5 years BU always reported negative net income.
In the past 5 years BU always reported negative operating cash flow.
BU.CA Yearly Net Income VS EBIT VS OCF VS FCFBU.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5M -10M -15M -20M -25M

1.2 Ratios

BU's Return On Assets of -26.96% is on the low side compared to the rest of the industry. BU is outperformed by 71.43% of its industry peers.
With a Return On Equity value of -119.03%, BU is not doing good in the industry: 78.57% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -26.96%
ROE -119.03%
ROIC N/A
ROA(3y)-113.59%
ROA(5y)-75.48%
ROE(3y)-292.02%
ROE(5y)-182.82%
ROIC(3y)N/A
ROIC(5y)N/A
BU.CA Yearly ROA, ROE, ROICBU.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for BU so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
BU.CA Yearly Profit, Operating, Gross MarginsBU.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -5K -10K -15K

More info and screens

2

2. Health

2.1 Basic Checks

BU does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for BU has been increased compared to 1 year ago.
Compared to 5 years ago, BU has more shares outstanding
Compared to 1 year ago, BU has a worse debt to assets ratio.
BU.CA Yearly Shares OutstandingBU.CA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M 8M 10M
BU.CA Yearly Total Debt VS Total AssetsBU.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M

2.2 Solvency

BU has an Altman-Z score of -6.27. This is a bad value and indicates that BU is not financially healthy and even has some risk of bankruptcy.
BU's Altman-Z score of -6.27 is on the low side compared to the rest of the industry. BU is outperformed by 75.00% of its industry peers.
BU has a Debt/Equity ratio of 2.80. This is a high value indicating a heavy dependency on external financing.
BU's Debt to Equity ratio of 2.80 is on the low side compared to the rest of the industry. BU is outperformed by 75.00% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.8
Debt/FCF N/A
Altman-Z -6.27
ROIC/WACCN/A
WACC6.66%
BU.CA Yearly LT Debt VS Equity VS FCFBU.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10M 20M 30M

2.3 Liquidity

BU has a Current Ratio of 1.82. This is a normal value and indicates that BU is financially healthy and should not expect problems in meeting its short term obligations.
The Current ratio of BU (1.82) is comparable to the rest of the industry.
A Quick Ratio of 1.77 indicates that BU should not have too much problems paying its short term obligations.
BU has a better Quick ratio (1.77) than 75.00% of its industry peers.
Industry RankSector Rank
Current Ratio 1.82
Quick Ratio 1.77
BU.CA Yearly Current Assets VS Current LiabilitesBU.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for BU have decreased strongly by -1323.48% in the last year.
Looking at the last year, BU shows a very strong growth in Revenue. The Revenue has grown by 111.89%.
BU shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 66.28% yearly.
EPS 1Y (TTM)-1323.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1578.59%
Revenue 1Y (TTM)111.89%
Revenue growth 3Y30.91%
Revenue growth 5Y66.28%
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
Based on estimates for the next years, BU will show a very strong growth in Revenue. The Revenue will grow by 228.16% on average per year.
EPS Next Y143.99%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year153.85%
Revenue Next 2Y228.17%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
BU.CA Yearly Revenue VS EstimatesBU.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 5M 10M
BU.CA Yearly EPS VS EstimatesBU.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2020 2021 2022 2023 2024 2025 2026 0 -1 -2 -3

More info and screens

3

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for BU. In the last year negative earnings were reported.
With a Price/Forward Earnings ratio of 8.45, the valuation of BU can be described as very reasonable.
BU's Price/Forward Earnings ratio is rather cheap when compared to the industry. BU is cheaper than 96.43% of the companies in the same industry.
Compared to an average S&P500 Price/Forward Earnings ratio of 36.28, BU is valued rather cheaply.
Industry RankSector Rank
PE N/A
Fwd PE 8.45
BU.CA Price Earnings VS Forward Price EarningsBU.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
BU.CA Per share dataBU.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4 -0.4 -0.6

4.3 Compensation for Growth

BU's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

BU does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BURCON NUTRASCIENCE CORP

TSX:BU (8/5/2025, 7:00:00 PM)

2.88

+0.03 (+1.05%)

Chartmill FA Rating
GICS SectorMaterials
GICS IndustryGroupMaterials
GICS IndustryChemicals
Earnings (Last)06-25 2025-06-25/amc
Earnings (Next)08-12 2025-08-12
Inst Owners5.92%
Inst Owner ChangeN/A
Ins Owners30.46%
Ins Owner ChangeN/A
Market Cap36.55M
Analysts84.44
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-91.86%
Min Revenue beat(2)-95.36%
Max Revenue beat(2)-88.35%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)1900%
Revenue NQ rev (1m)-89.47%
Revenue NQ rev (3m)-89.47%
Revenue NY rev (1m)-69.16%
Revenue NY rev (3m)-69.16%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 8.45
P/S 95.82
P/FCF N/A
P/OCF N/A
P/B 5.26
P/tB 6.42
EV/EBITDA N/A
EPS(TTM)-0.77
EYN/A
EPS(NY)0.34
Fwd EY11.83%
FCF(TTM)-0.46
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.03
BVpS0.55
TBVpS0.45
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -26.96%
ROE -119.03%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-113.59%
ROA(5y)-75.48%
ROE(3y)-292.02%
ROE(5y)-182.82%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 2.8
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 36.37%
Cap/Sales 79.58%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.82
Quick Ratio 1.77
Altman-Z -6.27
F-Score3
WACC6.66%
ROIC/WACCN/A
Cap/Depr(3y)68.17%
Cap/Depr(5y)195.49%
Cap/Sales(3y)82.83%
Cap/Sales(5y)124.04%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1323.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1578.59%
EPS Next Y143.99%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)111.89%
Revenue growth 3Y30.91%
Revenue growth 5Y66.28%
Sales Q2Q%N/A
Revenue Next Year153.85%
Revenue Next 2Y228.17%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year130.44%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1.49%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y4.57%
OCF growth 3YN/A
OCF growth 5YN/A